An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Dexaflox Eye Drops Containing Ofloxacin (3 mg) and dexamethasone (1 mg) in Subjects with Bacterial Conjunctivitis

drug protocol number
DEXA001
drug sponsor
Jamjoom Pharmaceuticals
drug study
Dexaflox
drug trial site
King Khalid University Hospital (Riyadh)
drug status
Completed
drug phase